What Makes This Biotech A “Strong Buy”? An Underappreciated – And Potentially Transformative – Late-Stage Pipeline
The biotech featured in today’s article “selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a significant benefit over existing products.”